In the studies quoted below, recombinant (= artificially synthesized) DAF and CAR receptors were experimentally injected into mice that had coxsackievirus B infections. DAF and CAR are receptors are normally located on the surface of the cell, and coxsackievirus B latches onto these receptors in order to break into and infect a cell. It would appear that by injecting these artificial, recombinant DAF and CAR receptors into the mice, the coxsackieviruses attached to the recombinant DAF and CAR receptors instead, rather than the real DAF and CAR receptors on the mice's cells. Doing this blocked the coxsackievirus infection. This might translate to a chronic fatigue syndrome treatment option in the future, as of course ME/CFS is strongly linked to chronic coxsackievirus B infection. It looks promising.